Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease - Trial NCT06356662
Access comprehensive clinical trial information for NCT06356662 through Pure Global AI's free database. This Phase 1 trial is sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine and is currently Recruiting. The study focuses on Parkinson Disease. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Timeline & Enrollment
Phase 1
Jan 23, 2024
Dec 31, 2024
Primary Outcome
UPDRS III๏ผUnified Parkinson's Disease Rating Scale part 3๏ผ
Summary
To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of
 Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in
 early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take
 Tenofovir disoproxil fumarate at different time points were compared.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06356662
Non-Device Trial